LGALS9 and infection: As expected, the anti-ACE2 antibody blocked SARS-2-S, but not VSV-G, entry in a dose-dependent manner (P < 0.05) (Figure 2C) and also blocked Gal-9-enhanced SARS-2-S infection (P < 0.01) (Figure 2D), indicating that Gal-9 facilitates SARS-CoV-2 entry in an ACE2-dependent manner.